Thrombotic Management of Antiphospholipid Syndrome: Towards Novel Targeted Therapies

Author(s): Md. Asiful Islam*, Fahmida Alam, Kah Keng Wong, Mohammad Amjad Kamal, Siew Hua Gan*

Journal Name: Current Vascular Pharmacology

Volume 15 , Issue 4 , 2017

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by thrombosis and/or pregnancy morbidity with persistent levels of antiphospholipid antibodies (aPLs). The development of thrombosis in APS is mediated by aPLs and contributes to the high mortality rate in APS patients. However, although APS has been reported for more than 30 years, there has been no optimal regimen for its prevention or for the management of thrombosis, mainly because the mainstay treatment strategies for managing APS are not targeted towards aPL-mediated thrombotic pathophysiology. Instead, the treatments commonly used are aimed at general thrombotic disorders. Warfarin is the most commonly used vitamin K antagonist (VKA), in addition to anti-platelet medications, such as aspirin and clopidogrel. Over the last decade, novel non-VKA oral anticoagulants, including rivaroxaban, apixaban and dabigatran, as well as immunomodulatory agents, such as rituximab, eculizumab, hydroxychloroquine, statins and sirolimus, have also been used. In this review, we discuss the current treatment strategies and future treatment outlook for thrombotic APS.

Keywords: Antiphospholipid syndrome, antiphospholipid antibodies, thrombosis, treatment, anticoagulant, anti-platelet agents.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 05 January, 2017
Page: [313 - 326]
Pages: 14
DOI: 10.2174/1570161115666170105120931
Price: $65

Article Metrics

PDF: 86
HTML: 12
PRC: 1